Akero Therapeutics, Inc.: cash and cash equivalents

What this measure means

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2018-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Akero Therapeutics, Inc.: total assets
• Akero Therapeutics, Inc.: total liabilities
• Akero Therapeutics, Inc.: stockholders equity
• Akero Therapeutics, Inc.: net income or loss
• Akero Therapeutics, Inc.: operating cash flow
• Akero Therapeutics, Inc.: financing cash flow
• Akero Therapeutics, Inc.: investing cash flow
• Akero Therapeutics, Inc.: retained earnings or deficit
• Akero Therapeutics, Inc.: basic weighted-average shares
• Akero Therapeutics, Inc.: diluted weighted-average shares
• Akero Therapeutics, Inc.: basic earnings per share
• Akero Therapeutics, Inc.: diluted earnings per share
• Akero Therapeutics, Inc.: net property, plant and equipment
• Akero Therapeutics, Inc.: share-based compensation expense
• Akero Therapeutics, Inc.: operating income or loss
• Akero Therapeutics, Inc.: current assets
• Akero Therapeutics, Inc.: interest expense
• Akero Therapeutics, Inc.: current liabilities
• Akero Therapeutics, Inc.: current accounts payable
• Akero Therapeutics, Inc.: research and development expense

Inspect the source

Entity

Akero Therapeutics, Inc. / CIK 0001744659

Captured

2026-09-21T17:25:41.770Z

SEC response SHA-256

0ae7d2448decd0f23c1f21654b9424b49076438dd111b2ab06afb1f794330bf1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001744659.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))